Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: A retrospective clinical study

British Journal of Radiology

Volumn 87, Issue 1035, 2014, Pages

  Ji, K ^a   Zhao, L J ^a   Liu, W S ^a   Liu, Z Y ^a   Yuan, Z Y ^a   Pang, Q S ^a   Wang, J ^a   Wang, P ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL STUDY; COMPUTED TOMOGRAPHY SCANNER; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; LOCAL RECURRENCE FREE SURVIVAL; MALE; MULTILEAF COLLIMATOR; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SIMULTANEOUS INTEGRATED BOOST INTENSITY MODULATED RADIOTHERAPY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THERAPY EFFECT; VERY ELDERLY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIATION PNEUMONIA; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84908267957     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20130562     Document Type: Article

References (24)

1. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III nonsmall cell lung cancer: randomized Phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-60. doi: 10.1093/jnci/djr325
2. Kong FM, Ten HR, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63: 324-33.
3. Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild SE, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy 1/2 cetuximab for stage IIIa/IIIb non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617. Proceedings of the 53rd Annual Meeting of the American Society of Radiation Oncology; 2-6 October 2011; Miami, FL. Washington, DC: American Society for Radiation Oncology, 2011.
4. Movsas B, Hu C, Sloan J, Bradley JD, Kavadi VS, Narayan S, et al. Quality of life (QOL) analysis of the randomized radiation (RT) dose-escalation NSCLC trial (RTOG 0617): the rest of the story. Proceedings of the 55rd Annual Meeting of the American Society of radiation Oncology; 22-25 September 2013; Atlanta, GA. Washington, DC: American Society for Radiation Oncology, 2013.
5. Studer G, Peponi E, Kloeck S, Dossenbach T, Huber G, Glanzmann C. Surviving hypopharynx-larynx carcinoma in the era of IMRT. Int J Radiat Oncol Biol Phys 2010; 77: 1391-6. doi: 10.1016/j.ijrobp.2009.07.005
6. McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypo-fractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 75: 413-20.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
8. Kepka L, Tyc-Szczepaniak D, Bujko K. Doseperfraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced nonsmall cell lung cancer. J Thorac Oncol 2009; 4: 853-61. doi: 10.1097/JTO.0b013e3181a97dda
9. Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 Phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer 2000; 36: 592-600.
10. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43: 114-21. doi: 10.1016/j.ejca.2006.09.005
11. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98. doi: 10.1016/j.lungcan.2004.03.004
12. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-17.
13. Turner LM, Howard JA, Dehghanpour P, Barrett RD, Rebueno N, Palmer M, et al. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim 2011; 36: 383-8.
14. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005; 62: 988-94. doi: 10.1016/j.ijrobp.2004.12.019
15. Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 2007; 25: 5557-61. doi: 10.1200/JCO.2007.13.2191
16. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009; 4: 5. doi: 10.1186/1748-717X-4-5
17. Zhao L, Chen M, Ten HR, Chetty I, Chapet O, Hayman JA, et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative nonsmall cell lung cancer when the tumor is large and centrally located. Radiother Oncol 2007; 82: 153-9.
18. Kimura T, Togami T, Nishiyama Y, Ohkawa M, Takashima H. Impact of incidental irradiation on clinically uninvolved nodal regions in patients with advanced non-small-cell lung cancer treated with involved-field radiation therapy: does incidental irradiation contribute to the low incidence of elective nodal failure? Int J Radiat Oncol Biol Phys 2010; 77: 337-43.
19. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, et al. Dosevolume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 329-39.
20. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67: 275-83.
21. Kim TH, Cho KH, Pyo HR, Lee JS, Zo JI, Lee DH, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005; 235: 208-15. doi: 10.1148/radiol.2351040248
22. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of treatmentrelated pneumonitis in advanced-stage nonsmall- cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 94-102.
23. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008; 87: 17-23. doi: 10.1016/j.radonc.2008.02.005
24. Thames HJ, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219-26.